Clinical trial
Study of rhASB in Patients With Mucopolysaccharidosis VI
NCT00104234 · BioMarin Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00104234 |
|---|---|
| Title | Study of rhASB in Patients With Mucopolysaccharidosis VI |
| Official title | A Multicenter, Multinational Open-Label Extension Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With Mucopolysaccharidosis VI |
| Lead sponsor | BioMarin Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Mucopolysaccharidosis VI |
| Intervention type | Drug |
| Interventions | N-acetylgalactosamine 4-sulfatase, Placebo/rhASB |
| Enrollment | 39 |
| Start date | Feb 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Feb 25, 2005 |
| Last update posted | Feb 2, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: